VivoSeq
Other

Exanthem

2

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Exanthem is an early-stage landscape with 2 programs across 1 company. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

N/A

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Approved

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved2

Pimecrolimus

Bausch Health Americas, Inc.

Hydrocortisone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)